USPTO Examiner WELLS LAUREN QUINLAN - Art Unit 1622

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
190381371-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDSJanuary 2025December 2025Allow1010NoNo
18985720DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORSDecember 2024May 2025Allow510YesNo
18973200RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARISDecember 2024September 2025Allow920YesNo
18923566MrgprX2 Antagonists for the Treatment of Inflammatory DisordersOctober 2024September 2025Allow1122YesNo
18912939RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARISOctober 2024August 2025Abandon1010NoNo
18884941METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONSSeptember 2024March 2026Abandon1830YesNo
18812527MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOFAugust 2024March 2025Allow711YesNo
18759222TOPICAL FORMULATIONS FOR INFECTIONSJune 2024November 2025Allow1721YesNo
18661306METHOD OF TREATING SEIZURES AND EPILEPSY USING LIQUID PHARMACEUTICAL COMPOSITION FOR ORAL DOSAGE OF VIGABATRINMay 2024September 2025Allow1710NoNo
18658848METHODS AND COMPOSITIONS FOR TARGETING PD-L1May 2024September 2025Allow1611YesNo
18652993RAMIPRIL SOLUTION FOR ORAL DOSAGEMay 2024May 2025Allow1221YesNo
18646365COMPOSITION COMPRISING LIPOIC ACID AND VITAMIN D FOR THE PREVENTION AND THE TREATMENT OF NEURODEGENERATIVE DISEASES AND PERIPHERAL NEUROPATHIESApril 2024December 2025Abandon1910NoNo
18638340OTIC FORMULATIONS, METHODS AND DEVICESApril 2024August 2025Allow1610NoNo
18602482PAIN TREATING COMPOUNDS AND USES THEREOFMarch 2024January 2026Abandon2311NoNo
18591969CRYSTALLINE SALTS OF PSILOCINFebruary 2024March 2025Allow1201YesNo
18591925CRYSTALLINE SALTS OF PSILOCINFebruary 2024March 2025Allow1201YesNo
18685899ABIRATERONE PRECURSOR COMPOUND AND PREPARATION METHOD AND USE THEREOFFebruary 2024June 2025Allow1621YesNo
18407729FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERSJanuary 2024July 2025Abandon1910NoNo
18544952NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USEDecember 2023August 2025Allow2010NoNo
18529689TEAD INHIBITORS AND METHODS OF USES THEREOFDecember 2023April 2024Allow501YesNo
18506138ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACIDNovember 2023January 2026Allow2621YesNo
18278628PHARMACEUTICAL COMPOSITION OF FORSKOLIN-ISOFORSKOLIN AND PENTACYCLIC TRITERPENOID COMPOUND, AND APPLICATION THEREOFOctober 2023June 2025Abandon2221NoNo
18486668TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USEOctober 2023September 2025Allow2411YesNo
18480898RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARISOctober 2023March 2025Abandon1710NoNo
18370069CLEAVABLE CONJUGATES OF CATECHOL COMPOUNDS AND WATER-SOLUBLE POLYMERS AND METHODS OF TREATMENT USING THE SAMESeptember 2023February 2026Allow2921YesNo
18279031COMPOSITIONS AND METHODS FOR THE TREATMENT OF PLASMODIUM FALCIPARUM MALARIAAugust 2023September 2025Allow2511YesNo
18236839Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side EffectsAugust 2023July 2025Abandon2311NoNo
18344336RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENSJune 2023August 2024Allow1401YesNo
18344555POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4June 2023December 2024Abandon1701NoNo
18340006METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTIONJune 2023November 2023Allow410NoNo
18338717USE OF FATTY ACID OXIDATION INHIBITORS AS ANTIMICROBIALSJune 2023December 2025Allow3030NoNo
18337623PRODUCTION METHOD FOR RADIOLABELED ARYL COMPOUNDJune 2023June 2025Allow2321YesNo
18267202DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORSJune 2023March 2026Allow3300YesNo
18208025METHOD FOR DIFFERENTIALLY DIAGNOSING ACTH-DEPENDENT CUSHING'S SYNDROMEJune 2023October 2024Abandon1601NoNo
18202681SELECTIVE DETECTION OF BED BUGSMay 2023March 2025Allow2111YesNo
18311126STABLE LIQUID VIGABATRIN PHARMACEUTICAL COMPOSITION FOR ORAL DOSAGEMay 2023May 2024Allow1201YesNo
18304270PHOSPHOLIPID COMPOUNDS AND USES THEREOFApril 2023February 2024Allow1011YesNo
18301099METHOD AND COMPOSITION FOR TREATING CNS DISORDERSApril 2023September 2025Allow3021YesNo
18300312COMBINATION THERAPY FOR PI3K-ASSOCIATED DISEASE OR DISORDERApril 2023November 2024Abandon1901NoNo
18129267Methods for the Prevention and Treatment of Hearing Loss using OseltamivirMarch 2023April 2024Allow1311YesNo
18128075COMPOSITIONS AND METHODS FOR TREATING RENAL INJURYMarch 2023February 2025Abandon2311NoNo
18184618DIETARY CHOLINE SUPPLEMENTATION TO REDUCE TUMOR VOLUME AND ENHANCE COGNITIVE RESPONSE DURING CANCER TREATMENTMarch 2023July 2024Abandon1711NoNo
18184513SYSTEMIC ISOXAZOLINE PARASITICIDES FOR VECTOR-BORNE AND VIRAL DISEASE TREATMENT OR PROPHYLAXISMarch 2023September 2025Abandon3040YesYes
18120189METHODS FOR IDENTIFYING PRE-DISPOSITION TO COGNITIVE DECLINE AND AGENTS FOR REDUCING OR PREVENTING COGNITIVE DECLINE, OR IMPROVING COGNITIVE ABILITYMarch 2023November 2025Allow3241YesNo
18160897COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMOJanuary 2023March 2024Abandon1401NoNo
18017471APPLICATION OF ARTEMISININ COMPOUND IN TREATMENT OF CORONAVIRUS INFECTIONJanuary 2023March 2026Abandon3810NoNo
18006125USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAINJanuary 2023March 2026Abandon3810NoNo
18153954PROPHYLAXIS AND REVERSAL OF STIMULANT AND OPIOID/OPIATE OVERDOSE AND/OR TOXIC EXPOSUREJanuary 2023January 2024Abandon1201NoNo
18146698COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERSDecember 2022November 2024Allow2211YesNo
18146393COMPOSITIONS COMPRISING CAROTENOIDS, METHODS AND APPLICATION THEREOFDecember 2022February 2025Abandon2621YesNo
18063695USE OF TETRANDRINE IN COMBINATION WITH ALL-TRANS RETINOIC ACID IN PREPARATION OF MEDICAMENT FOR TREATING PNEUMOCONIOSISDecember 2022January 2025Abandon2521NoNo
18075163DISULFIRAM DERIVATIVES AS ALDH1A1 AND MAGL INHIBITORSDecember 2022September 2024Allow2210YesNo
17992254FENFLURAMINE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH SPREADING DEPOLARIZATIONNovember 2022January 2025Abandon3621NoNo
17985740TREATING LIVER DISORDERS WITH AN SSAO INHIBITORNovember 2022February 2025Abandon2821NoNo
18053648COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTIONNovember 2022September 2025Abandon3440YesYes
17970933TOPICAL TRANEXAMIC ACID COMPOSITIONS AND METHODS OF USE THEREOFOctober 2022March 2023Allow510YesNo
17965569COMPOUNDS FOR TARGETED DEGRADATION OF BRD9October 2022November 2023Allow1311YesNo
17915123USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)September 2022March 2025Allow2931YesNo
17954319COMPOSITION FOR MODULATING HYDROGEN ION PHYSIOLOGY RELATED TO BRAIN HEALTH COMPONENTSeptember 2022August 2024Abandon2321YesNo
17934625PYRIDAZINESSeptember 2022December 2023Allow1421YesNo
17948180PSILOCYBIN DERIVED COMPOSITIONS AND METHODS USING SAMESeptember 2022August 2025Allow3531YesNo
17906045JAK KINASE INHIBITOR AND PREPARATION AND APPLICATION THEREOFSeptember 2022January 2026Abandon4010NoNo
17908858CRYSTAL FORMS OF METHYL(2R*,4R*)-4-[[(5S)-3-(3,5-DIFLUOROPHENYL)-5-VINYL-4H-ISOXAZOLE-5-CARBONYL]AMINO]TETRAHYDROFURAN-2-CARBOXYLATE AND THEIR HERBICIDAL SYNERGISTIC EFFECTSSeptember 2022February 2026Allow4220YesNo
17901775COMPOUNDS FOR TARGETED DEGRADATION OF BRD9September 2022February 2024Allow1810NoNo
17895667PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTSAugust 2022December 2025Abandon3901NoNo
17818846CRYSTALLINE FORM OF TOLEBRUTINIBAugust 2022March 2023Allow811YesNo
17807083METHODS AND COMPOSITIONS FOR TARGETING PD-L1June 2022February 2024Allow2011NoNo
17782780PHARMACEUTICAL COMPOSITION, COMPLEMENTARY KIT AND APPLICATION THEREOFJune 2022December 2025Abandon4210NoNo
17751998CRYSTALLINE SALTS OF PSILOCINMay 2022December 2023Allow1811YesNo
17752526USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASEMay 2022October 2024Abandon2920NoNo
17749082PROPHYLAXIS AND REVERSAL OF STIMULANT AND OPIOID/OPIATE OVERDOSE AND/OR TOXIC EXPOSUREMay 2022August 2023Abandon1520NoNo
17736773IMPROVING THE QUALITY OF HUMAN OOCYTESMay 2022August 2024Abandon2721YesNo
17734601LSD AND PSILOCYBIN DOSE EQUIVALENCE DETERMINATIONMay 2022April 2025Abandon3631NoNo
17721789COMPOSITIONS AND METHODS FOR PROMOTING SLEEPApril 2022April 2024Abandon2411NoNo
17697039COMPOSITIONS AND METHODS FOR TREATMENT OF FRAGILE X SYNDROMEMarch 2022September 2025Allow4211NoNo
17689607CANNABINOIDS IN THE TREATMENT OF EPILEPSYMarch 2022October 2025Abandon4310YesNo
17678990TREATMENT OF A RESPIRATORY CORONAVIRUS INFECTION WITH NITROXIDESFebruary 2022May 2023Abandon1520YesNo
17628848COMBINATION TREATMENT OF LIVER DISEASES USING FXR AGONISTSJanuary 2022August 2025Abandon4301NoNo
17624792METHOD FOR PREVENTING HAIR LOSSJanuary 2022September 2025Allow4511YesNo
17623477CAPACITATIVE CALCIUM ENTRY INHIBITORSDecember 2021June 2025Abandon4201NoNo
17618345COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITYDecember 2021December 2025Abandon4811NoNo
17545864COMPOSITIONS AND METHODS FOR REDUCING CANCER STEM CELL GROWTHDecember 2021March 2024Allow2740YesNo
17541035COMPOUNDS FOR TARGETED DEGRADATION OF BRD9December 2021May 2022Allow611NoNo
17540826DISULFIRAM DERIVATIVES AS ALDH1A1 AND MAGL INHIBITORSDecember 2021May 2023Allow1731YesYes
17595772DIAZEPINONE DERIVATIVES AS CAPSID ASSEMBLY MODULATORSNovember 2021May 2025Abandon4110NoNo
17612957OXATHIAZIN_DIOXIDE FOR TREATING, PREVENTING, INHIBITING OR REDUCING CYTOKINE RELEASENovember 2021November 2025Allow4821YesNo
17610531MATRIX COMPOSITION COMPRISING (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROBENZO[B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDENovember 2021October 2025Abandon4701NoNo
17607632METHODS OF TREATING PRURITUSOctober 2021June 2025Abandon4331YesNo
17515372METHOD FOR PRODUCING ORAL DISINTEGRATING FILM COMPRISING POORLY SOLUBLE DRUGOctober 2021April 2024Abandon2941YesNo
17607464SALT OF DIAMINOPYRIMIDINE COMPOUNDS, AND SOLID FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOFOctober 2021July 2025Allow4411YesNo
17507970COMPOSITIONS OF AUTOPHAGY MODULATING AGENTS AND USES THEREOFOctober 2021August 2025Allow4531YesNo
17503126LIQUID PHARMACEUTICAL COMPOSITIONSOctober 2021January 2024Abandon2710NoNo
17502559PHOSPHOLIPID COMPOUNDS AND USES THEREOFOctober 2021September 2024Allow3531YesNo
17604371COMBINATION THERAPYOctober 2021December 2024Abandon3821NoNo
17501799MONO-(ACID) SALTS OF 6-AMINOISOQUINOLINES AND USES THEREOFOctober 2021December 2025Abandon5021NoNo
17594144SYSTEMIC ISOXAZOLINE PARASITICIDES FOR VECTOR-BORNE AND VIRAL DISEASE TREATMENT OR PROPHYLAXISOctober 2021October 2025Abandon4840NoYes
174885682-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORSSeptember 2021December 2024Abandon3811NoNo
17440879NOVEL AZAINDOLE DERIVATIVESeptember 2021April 2025Abandon4310NoNo
17439611PKM2 MODULATORS AND METHODS FOR THEIR USESeptember 2021April 2025Abandon4301NoNo
17472647Method For Treating COVID-19 and Related Viral InfectionsSeptember 2021December 2023Abandon2721NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WELLS, LAUREN QUINLAN.

Strategic Value of Filing an Appeal

Total Appeal Filings
5
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
5
(100.0%)
Filing Benefit Percentile
0.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner WELLS, LAUREN QUINLAN - Prosecution Strategy Guide

Executive Summary

Examiner WELLS, LAUREN QUINLAN works in Art Unit 1622 and has examined 169 patent applications in our dataset. With an allowance rate of 34.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.

Allowance Patterns

Examiner WELLS, LAUREN QUINLAN's allowance rate of 34.9% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WELLS, LAUREN QUINLAN receive 2.12 office actions before reaching final disposition. This places the examiner in the 57% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WELLS, LAUREN QUINLAN is 40 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +60.2% benefit to allowance rate for applications examined by WELLS, LAUREN QUINLAN. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.4% of applications are subsequently allowed. This success rate is in the 32% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 19.6% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 78.9% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.8% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.